Business Context and Reporting Period
This Form 8-K is a current report filed by The Beauty Health Company (trading symbol: SKIN) on February 25, 2025. The filing addresses the formal designation of two existing officers as executive officers subject to Section 16 of the Securities Exchange Act of 1934 due to the expansion of their duties to include policy-making functions.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements and corporate governance updates.
Material Changes
The primary material change disclosed is the elevation of Ronald Menezes (Chief Revenue Officer) and Sheri Lewis (Chief Supply Chain and Operations Officer) to the status of Section 16 Officers. This change triggers specific reporting obligations regarding their ownership and trading of company securities.
Management Commentary and Compensation Details
The filing details the compensation packages for the newly designated officers, which were originally effective in 2024 but are now formally disclosed in this context:
- Ronald Menezes (Chief Revenue Officer):
- Annual Base Salary: $450,000
- One-time Cash Bonus: $100,000 (subject to clawback if resigning voluntarily within one year)
- Annual Discretionary Bonus Target: 60% of base salary
- Equity Award: $800,000 in Restricted Stock Units (RSUs) vesting over three years
- Sheri Lewis (Chief Supply Chain and Operations Officer):
- Annual Base Salary: $485,000
- One-time Cash Bonus: $75,000 (subject to clawback if resigning voluntarily within one year)
- Annual Discretionary Bonus Target: 60% of base salary
- Equity Award: $1,181,250 in RSUs and $393,750 in Performance-Based RSUs (PSUs), vesting over three years
Both executives are eligible for future grants under the Company's 2021 Incentive Award Plan and standard employee benefit programs.
Investor Verification Checklist
- Verify the vesting schedules and performance conditions for the RSUs and PSUs granted to Menezes and Lewis in the attached offer letters (Exhibits 10.1 and 10.2).
- Monitor future Form 4 filings for insider trading activity by Menezes and Lewis, as they are now Section 16 Officers.
- Review the Company's 2021 Incentive Award Plan to understand the terms for potential future equity grants.
- Confirm the effective dates of the original appointments (October 15, 2024, for Menezes; April 9, 2024, for Lewis) to assess the timing of bonus eligibility.